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Background: Skeletal muscle stem cells enable the formation, growth, maintenance, and regeneration of skeletal
muscle throughout life. The regeneration process is compromised in several pathological conditions, and muscle
progenitors derived from pluripotent stem cells have been suggested as a potential therapeutic source for tissue
replacement. DNA methylation is an important epigenetic mechanism in the setting and maintenance of cellular
identity, but its role in stem cell determination towards the myogenic lineage is unknown. Here we addressed the
DNA methylation dynamics of the major genes orchestrating the myogenic determination and differentiation
programs in embryonic stem (ES) cells, their Pax7-induced myogenic derivatives, and muscle stem cells in
proliferating and differentiating conditions.
Results: Our data showed a common muscle-specific DNA demethylation signature required to acquire and
maintain the muscle-cell identity. This specific-DNA demethylation is Pax7-mediated, and it is a prime event in
muscle stem cells gene activation. Notably, downregulation of the demethylation-related enzyme Apobec2 in
ES-derived myogenic precursors reduced myogenin-associated DNA demethylation and dramatically impaired
the expression of differentiation markers and, ultimately, muscle differentiation.
Conclusions: Our results underscore DNA demethylation as a key mechanism driving myogenesis and identify
specific Pax7-mediated DNA demethylation signatures to acquire and maintain the muscle-cell identity. Additionally,
we provide a panel of epigenetic markers for the efficient and safe generation of ES- and induced pluripotent
stem cell (iPS)-derived myogenic progenitors for therapeutic applications.
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Developmental signals induce changes in gene expres-
sion and chromatin structure in order to define cell
identity. Epigenetic mechanisms, and DNA methylation
in particular, are essential for mammalian development
being involved in the establishment and maintenance of
cellular identity by creating cellular memory during em-
bryonic development [1–3]. DNA methylation controls
X-chromosome inactivation, expression of imprinted
genes, represses the transcription of repeated sequences
and prevents relocation of transposable elements (reviewed
in [4]). In addition, DNA methylation affects gene expres-
sion by regulating promoters and distal regulatory ele-
ments, such as enhancers and insulators (reviewed in [5]).* Correspondence: msuelves@imppc.org
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(http://creativecommons.org/publicdomain/zeIn the last few years, global analyses of DNA methylation
dynamics in pluripotent stem cells and their differentiated
progeny have begun to uncover the mechanisms involving
coordinated changes occurring in the epigenome that are
essential for lineage-specification and maintenance of
cellular identity [6–15]. Very recently, we reported the
genome-wide comparison of the DNA methylation pro-
files of pluripotent embryonic stem cells and muscle
stem cells showing, in agreement with other studies,
that cellular differentiation is associated with a modest
but global increase in DNA methylation, which inter-
estingly is accompanied by lineage-specific demethyla-
tion [16]. Although the mechanisms controlling DNA
demethylation are still not well defined, several studies
suggest the involvement of two major pathways in this
process: the activity of TET methylcytosine dioxygenase
proteins [17, 18] and AID/APOBEC cytidine deaminase
enzymes [19–21]. Importantly, active DNA demethylationis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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karyons derived from the fusion of human non-muscle
cells with mouse muscle cells, indicating a dynamic DNA
methylation/demethylation interplay during muscle differ-
entiation [22].
Skeletal muscle is the tissue accounting for the largest
percentage of body mass and contributes to multiple
body functions including the voluntary movements. The
skeletal muscle is mainly composed of highly specialized
and terminally differentiated multinuclear, post mitotic
and contractile myofibres, and a small pool of muscle
stem cells, known as satellite cells (SCs), which are
essential for the growth, maintenance and regeneration
of skeletal muscle throughout life (reviewed in [23]. The
transcriptional regulatory network controlling the estab-
lishment of muscle embryonic progenitors in the myo-
tome, as well as the activation of the satellite cells in the
adult, involves upregulation of myogenic regulatory
factors or MRFs (Myf5, MyoD, Mrf4 and Myog), as well
as silencing of other lineage-specifying genes (reviewed
in [24]). In addition, members of the Pax gene family
Pax3 and Pax7 lie upstream of MRFs and their expres-
sion is crucial to regulate muscle progenitor cell func-
tions [25, 26]. Pax7 is essential for the formation and
maintenance of SCs, being expressed in quiescent and
activated SCs, as well as in proliferating myogenic pro-
genitors [27].
In the present study, we addressed for the first time
the DNA methylation dynamics of the major genes or-
chestrating myogenic determination and differentiation
by comparing pluripotent ESCs, myogenic precursors
from Pax7-inducible ESCs, proliferating muscle stem
cells, and their respective myotube derivatives. Our
results showed a common muscle-specific DNA de-
methylation signature required to acquire and main-
tain the muscle-cell identity. Notably, downregulation
of the muscle-specific cytidine deaminase Apobec2 in
ES-derived myogenic precursors reduced myogenin-
associated DNA demethylation and dramatically affected
the expression of differentiation markers and, ultimately,
muscle differentiation.
Results
DNA methylation profile of myogenic genes harbouring
CpG island-promoters during myogenic differentiation
To elucidate DNA methylation dynamics associated with
skeletal myogenic lineage commitment and terminal dif-
ferentiation, we focused the analysis on genes known to
be associated with this process: developmental genes
(Pax3 and Pax7), myogenic regulatory factors (MyoD,
Myog and Mrf4) and terminal differentiation genes
(Myh1, Myh4, Myh8 and Ckm). Interestingly, these genes
could also be classified according to their CpG distribu-
tion, which represent sites of potential DNA methylation.Pax3, Pax7 and MyoD contain CpG islands (CGIs) in their
promoters, belonging to the CpG-rich genes category;
meanwhile, the other genes do not have CGI and their
promoters are considered CpG-poor. Using bisulphite
sequencing analysis, we compared the DNA methylation
state of undifferentiated ESCs and muscle stem cells,
isolated from adult skeletal muscle tissue, along with
respective differentiated myotubes and mature myofi-
bres (Fig. 1a). In addition, to assess whether the DNA
methylation events were muscle-lineage specific, we
analysed the methylation profiles of the following non-
myogenic cell lines: neuronal precursor cells (NPCs),
mouse embryonic fibroblasts (MEFs) and cardiomyocytes
(HL1). As shown in Additional file 1a, b, all analysed CGIs
in Pax3 and Pax7 regulatory regions were completely
unmethylated in all the samples. Similar results were pre-
viously reported for MyoD CGI [28]. These results were
expected since CGIs, usually located in the promoter
regions of housekeeping and developmental genes,
are known to be largely resistant to DNA methylation
[29–31].
Since DNA methylation often occurs in non-CGI re-
gions, we investigated whether enhancers and promoters
present a cell-specific deposition of this modification.
Previous studies of other groups identified two muscle-
specific regulatory regions upstream of the MyoD tran-
scription start site (TSS), located at -20 kb and -5 kb,
respectively [32–34]. Importantly, it was shown that the
distal MyoD enhancer located at -20 kb of the TSS was
modulated by DNA methylation in mouse tissues [31].
Therefore, we analysed the methylation status of Pax3
hypaxial somatic enhancer [35] located at -8 kb of the
Pax3 TSS, the Pax7 region containing the critical RBP-
Jκ binding site [36] located at -7,4 kb of Pax7 TSS, and
the two MyoD enhancer regions. As shown in Fig. 1b,
although these regulatory regions were totally or par-
tially methylated in ESCs and in non-muscle cells,
Pax3 and -20 kb MyoD enhancers were almost completely
free of methylation in myogenic cells, which correlates
with gene expression (Fig. 1b). On the contrary, the Pax7
and -5 kb distal regulatory region of MyoD were both
found highly methylated in muscle cells (Fig. 1b and
Additional file 1c), suggesting that their activation
would be independent of DNA methylation. Notably,
NPCs and HL1 cells presented high levels of Pax3 ex-
pression, despite high DNA methylation levels. This
result would suggest that the Pax3 hypaxial enhancer
might be mainly associated to enhance Pax3 expres-
sion in committed skeletal myogenic cells.
Next, to further characterize the epigenetic land-
scape involved in myogenic regulation, we took advan-
tage of publicly available ChIP-seq data of histone
post-translational modifications [37, 38]. As schema-
tized in Fig. 1c, Pax3, Pax7 and MyoD promoters
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Fig. 1 Epigenetic profile of myogenic genes harbouring a CpG island-promoter during myogenic differentiation. a Diagram of the myogenic
differentiation model and the main genes driving myogenesis. CpG-rich and CpG-poor promoter genes are indicated in green and in blue,
respectively. b Scheme of the Pax3, Pax7 and MyoD genes and their associated CGIs (green) and enhancer regions (red). DNA methylation and
expression of each gene were analysed in two biological duplicates of ESCs, myoblasts (MB), myotubes (MT), myofibres (MF), and NPC, HL1 and
MEF cell lines. Each circle represents a CpG dinucleotide, and its position relative to the TSS is indicated below. The colour gradient represents the
level of methylation indicated in the legend. Bar charts show gene expression values measured by qRT-PCR and normalized by 18S expression
(n = 2, mean ± SD). N.D. means non detectable. c Histone marks distribution and p300 binding in ESC (blue), MB (yellow) and MT (red) obtained
from ENCODE Project and Dynlatch’s lab [38]. CGIs CpG islands, ESCs embryonic stem cells, NPCs neuronal precursor cells, HL1 cardiomyocytes,
MEFs mouse embryonic fibroblasts, TSS transcription start site
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histone 3 trimethylated on lysine 4 (H3K4me3) and ly-
sine 27 (H3K27me3) in ESCs, which has been associ-
ated to poised transcription [39, 40]. This bivalent
state was clearly resolved in favour of the positive
mark H3K4me3 at myoblast (MB) and myotube (MT)
stages for MyoD, whereas the developmental genes
Pax3 and Pax7 retained the bivalent state (Fig. 1c).The analysis of these loci, including enhancer and dis-
tal regions, showed a gain in deposition of histone 3
monomethyl-lysine4 (H3K4me1), acetyl-lysine 27
(H3K27Ac) and increased recruitment of the p300
acetyltransferase at MB stage, and also at MTs in the
case of MyoD. Since MyoD is already higher expressed
in MBs, this maintenance of active enhancer marks in
MTs might be involved in keeping an open chromatin
Carrió et al. BMC Biology  (2016) 14:30 Page 4 of 15state of the region to maintain gene expression, rather
than promoting further transcriptional activation. All
together, these results indicate that the unmethylated
state of CGIs is conserved across the different cell
types, whereas Pax3 and -20 kb MyoD enhancer elem-
ent show cell type-specific dynamic methylation pat-
terns associated with changes in gene expression.
Myogenic-specific promoters undergo DNA
demethylation during muscle-lineage specification
Unlike MyoD, all the other MRFs Myf5, Mrf4 and Myog,
as well as the muscle differentiation markers display low
CpG content promoters. The analysis of the promoter
region, containing E-box and Mef2 binding sites, of
Myog and the other differentiation genes Ckm, Myh1,-3
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ESCs and non-muscle cells, correlating with gene silen-
cing, whereas the promoter regions in muscle cells were
unmethylated (Fig. 2a). Interestingly, these differenti-
ation genes became demethylated at the MB stage but
remained silenced. These myogenic genes were not
bivalent at the ESC stage and only presented active chro-
matin marks (H3K4me3 and H3K27Ac) in the promoter
regions according to their expression timing. Strikingly,
the terminal differentiation genes Myh1, Myh4 and
Myh8 gained the repressive mark H3K27me3 in MB
cells after DNA demethylation, suggesting that gene
expression was maintained epigenetically repressed by
PRC2 complex until the onset of the terminal differ-
entiation stage (Fig. 2b). Interestingly, Mrf4 followed9
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demethylated only in mature myofibres, where it is
specifically highly expressed (Fig. 2a).
We also investigated the epigenetic profile of highly
expressed pluripotency genes in ESC that become si-
lenced in MB and MT. Genes containing a CGI over-
lapping their promoter region, such as Sox2 and Fgf4,
were totally unmethylated in all cell types, whereas
genes with CpG-poor content promoters, such as
Dppa4 and Pou5f1, became highly hypermethylated
upon cellular differentiation (Additional file 2a, b). Re-
garding histone marks, ESC showed high levels of
H3K4me3 in the promoter regions of Sox2 and Fgf4,
whereas MB and MT cells gained H3K27me3 in associ-
ation with gene silencing (Additional file 2c). Dppa4
and Pou5f1 promoters presented also the active marks
H3K4me3 and H3K27Ac. However, in differentiating
cells the H3K27me3 mark was not acquired (Dppa4) or
in a very small extent (Pou5f1), leaving the gain of
DNA methylation as the postulated epigenetic silencing
mechanism (Additional file 2c).
All together, these results suggest that myogenic differ-
entiation genes become demethylated at CpG-poor regu-
latory regions during muscle-lineage determination, and
are maintained silenced by the polycomb repressive his-
tone mark H3K27me3 until gene activation. In contrast,
pluripotency gene silencing involves complete DNA
methylation or gain of H3K27me3 mark, depending on
promoter CpG context.
Pax7-induced ES-derived muscle differentiation
recapitulates myogenic DNA methylation changes
In order to recapitulate the commitment of myogenic
precursors during embryonic development, we utilized
mouse ES cells engineered to express Pax7 under the
control of a doxycycline-inducible promoter (iPax7)
[41]. At day 3 of embryoid body (EB) differentiation
Pax7 transgene expression was induced by doxycycline
(Dox), and at day 5 of EB differentiation the mesoder-
mal precursor cells (PDGFRα+/FLK1-) were sorted, with
or without Dox, and grown for 5 more days (Fig. 3a).
Importantly, only the iPax7-ES-derived myogenic pre-
cursors treated with Dox expressed myogenic differen-
tiation markers such as Myogenin, Ckm and Myh8 and
generated myotubes upon differentiation (Fig. 3b and
Additional file 3). To assess to what extent the iPax7-
ES-derived myogenic progenitors were epigenetically
reprogrammed, we evaluated the DNA methylation
state of the main myogenic genes in three independent
time courses. As expected, preliminary analysis revealed
the complete unmethylated state of the CGI located at
the Pax3 and MyoD promoter regions during the differ-
entiation process (data not shown). Importantly, the
CpG-poor myogenic regulatory regions also showed avery similar DNA methylation signature compared to
primary muscle stem cells and, interestingly, a stepwise
DNA demethylation was identified (Fig. 3c). The Pax3
hypaxial enhancer became completely demethylated at
day 3 of EB formation, independently of Pax7 induction
and despite the lack of Pax3 expression at any stage of
differentiation (Fig. 3b, c). Contrarily, the -20 kb enhancer
of MyoD, the -111 kb enhancer of Myf5 (where Pax7 is
bound) and Myf5 promoter became partially demethy-
lated at a later time and exclusively in Pax7-induced myo-
genic precursors, coinciding with the increase in mRNA
expression. Notably, at day 17 (iPax7-MTs) the demethy-
lated state persisted, despite the dramatic reduction of
MyoD and Myf5 expression levels (Fig. 3b, c). Myogenin
promoter showed a similar demethylation time course,
reaching a total loss of DNA methylation at the iPax7-
MB-precursor stage when Myogenin was slightly
expressed, and maintained in iPax7-MTs, when the
Myogenin gene showed the maximum expression level
(Fig. 3b, c). Interestingly, the promoters of the late dif-
ferentiation genes Myh8 and Ckm remained fully meth-
ylated until the iPax7-MT stage, when they became
partially demethylated simultaneously with gene activa-
tion (Fig. 3b, c). Importantly, we did not observe any
loss of DNA methylation in the absence of Pax7 expres-
sion in the control cells (no Dox treatment), indicating
that the observed demethylation was skeletal muscle-
specific. Finally, the analysis of the promoter regions of
the pluripotency genes Pou5f1 and Dppa4, which are
progressively silenced, showed a similar gain of DNA
methylation during cell differentiation as observed in
primary myoblasts (Fig. 3b, c).Impaired myogenic differentiation in Apobec2
knockdown myogenic precursors is associated with
reduced DNA demethylation
DNA demethylation at specific myogenic regulatory re-
gions was clearly observed in primary myoblasts and in
iPax7 ESC-derived myogenic precursors (Figs. 1b, 2a
and 3c). At first, we questioned whether the reported
demethylation could result from a passive loss of methy-
lation, in which the lack or the significant reduction of
DNA methyltransferases (Dnmts) coupled to the succes-
sive cell divisions would lead to the loss of this epigen-
etic mark. We analysed the expression levels of the
Dnmt1 responsible for the maintenance of the existent
DNA methylation pattern, and Dnmt3a and Dnmt3b,
which add de novo methyl groups after DNA replication.
All Dnmts were expressed, and, as shown in Additional
file 4, the expression levels of Dnmt1 and Dnmt3a did
not significantly change during EB differentiation, while
Dnmt3b expression decreased during cell differentiation
independently of Pax7 expression. These observations
Fig. 3 Pax7-engineered ESCs efficiently acquired the myogenic DNA methylation profile. a Experimental scheme of the differentiation protocol to
generate ES-derived myogenic progenitors using iPax7 mES cells (left). Pax7 induction assessed by qRT-PCR (right). b Expression profiles of markers
of pluripotency (Pou5f1 and Dppa4), muscle lineage commitment (Pax3, Myf5 and MyoD) and muscle differentiation (Myog, Ckm and Myh8) were
measured by qRT-PCR at the successive time points of iPax7 ESC-derived myogenic model and normalized by Gapdh expression (n = 3, mean ±
SD). c DNA methylation dynamics of Pax3, Myf5 and MyoD enhancers and CpG-poor promoters of muscle-specific genes (Myf5 Myog, Ckm and
Myh8) and pluripotency genes (Pou5f1 and Dppa4) during Pax7-induced myogenesis (+Dox shown in red and -Dox shown in black). The results of
three biological replicates are shown. Each circle represents a CpG dinucleotide and the colour gradient represents the level of methylation indicated
in the legend and assessed by sodium bisulphite sequencing. Demethylation waves occurring during the Pax7-induced myogenesis are
denoted by red dotted boxes. ESCs embryonic stem cells, Dox doxycycline; iPax7 inducible Pax7
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on muscle-related genes might be mediated by an active
mechanism rather than by a passive one.
The two major pathways involved in controlling the
DNA demethylation process are the oxidation-mediated
demethylation by TET proteins and the cytosine deamin-
ation by AID/APOBEC cytidine deaminase enzymes. The
expression levels of Tet1, Tet2 and Tet3 did not change in
the presence or absence of Pax7 expression during the EB
differentiation, as shown in Additional file 4b. However,
the expression levels of Apobec2, the skeletal muscle spe-
cific member of the AID/APOBEC family, were highly in-
duced upon Pax7-mediated muscle-commitment, being
very high at the progenitor stage and derived MTs (Fig. 4a).
Importantly, despite the lack of high specificity of the
Apobec2 antibody (Additional file 4c) a clear increase of
Apobec2 protein was observed by western-blot concomi-
tant with the differentiation progression (Fig. 4a).
In order to test whether Apobec2 is required for
the myogenic process, we performed loss of function
experiments by down-regulating Apobec2 levels using
lentiviral vectors encoding for specific shRNAs. To
identify the most appropriate time point for shRNA
viral-mediated transduction (before DNA demethyla-
tion has taken place) we performed and analysed a
daily time course starting from Dox-treated
PDGFRα+/FLK1- sorted cells from day 5 EBs until
iPax7-MB precursor stage (day 10). As shown in
Fig. 4b, we observed a perfect correlation between
gradual DNA demethylation of the Myogenin locus
and increased gene expression, which starts at EB day
9. Based on these data, we decided to transduce Dox-
treated PDGFRα+/FLK1- cells at day 6 of differentiation
using two different Apobec2 shRNAs (shRNA1 and
shRNA4). As expected, four days after transduction,
Apobec2 shRNAs dramatically knocked-down Apobec2
mRNA and protein levels (Fig. 4c) without affecting
Pax7 expression (data not shown). Importantly, Apo-
bec2 knockdown was associated with a severe down-
regulation of Myogenin expression, both at mRNA and
protein level and, ultimately, impairment of terminal
muscle differentiation (Fig. 4d). Interestingly, the
methylation analysis of the Myogenin promoter upon
Apobec2 knockdown showed a significant methylation
gain in 70 % of the promoter CpGs (Kruskal-Wallis
test, p-value < 0.05) compared to the control cells
(Fig. 4e). Finally, we also analysed the impact of Apo-
bec2 knockdown in MyoD and Myf5 DNA methylation
levels, and, as shown in Additional file 5a,b, although
we observed a small increase of methylation in some of
the CpGs, it was not statistically significant. All these
results together, suggest that Apobec2 might participate
more actively in the DNA demethylation process re-
quired to drive myogenic differentiation rather than inregulating the DNA methylation-dependent myogenic
commitment.Discussion
Tissue-specific stem cells are lineage-restricted cells that
have lost pluripotency capacities and gained cell-type
identity. Epigenetic regulation, including DNA methyla-
tion and the post-translational modifications of histones,
is crucial in the establishment and maintenance of cellu-
lar identity [1–3, 42]. In this study, we analysed for the
first time the DNA methylation dynamics of the princi-
pal genes orchestrating myogenic determination and dif-
ferentiation programs by comparing ES cells and their
Pax7-induced skeletal myogenic derivatives with muscle
stem cells, both in proliferating and differentiating con-
ditions. The detailed analysis of CpG-poor regulatory
regions for the developmental gene Pax3, MyoD and
Myogenin genes as muscle cell-identity transcription
factors, and Ckm, Mhy1, Myh4 and Myh8 as myogenic
terminal differentiation genes revealed a specific DNA
demethylation signature required to acquire and main-
tain muscle-cell identity during the establishment of the
muscle lineage (Figs. 1b, 2a and 3c). These results
reinforce observations reported in other cellular models
that lineage-specific DNA demethylation, together with
pluripotency genes hypermethylation, occur during early
cell fate decisions conferring unique DNA methylation
patterns which correlate with defined cellular identities
[43–46]. Interestingly, our results showed that the cru-
cial myogenic differentiation factor Myogenin became
fully demethylated in muscle-committed cells before
gene expression (Fig. 2a). However, these results were in
disagreement with previous work performed in C2C12
cells where loss of methylation was observed between
myoblasts and myotubes [47, 48]. To address this con-
troversy, we isolated freshly satellite cells from adult
mice, and, interestingly, the DNA methylation analysis
of the Myogenin promoter revealed the complete de-
methylation of the promoter in ex vivo isolated muscle
stem cells (unpublished data). These results would indi-
cate that DNA demethylation of Myogenin promoter oc-
curs during muscle-lineage determination, allowing the
acquisition of a transcriptional poised state before gene
expression during muscle differentiation. Notably, gene
silencing of terminal differentiation Myosin genes in
proliferating myoblasts upon DNA demethylation is
maintained by the acquisition of the Polycomb repres-
sive mark H3K27me3 (Fig. 2b), as previously reported
for Myog and Ckm promoters [49, 50]. During terminal
differentiation, H3K27me3 is replaced by the positive
marks H3K4me3 and H3K27Ac, which result in gene
transcription. This two-step repressive mechanism,
where DNA methylation is replaced by H3K27me3, is
Fig. 4 Impaired myogenic progression and differentiation and reduced DNA demethylation in Apobec2 knockdown myogenic precursors. a Time course of
Apobec2 expression during differentiation of iPax7 ES cells in presence or absence of Pax7, which was induced by adding doxycycline (Dox) to the culture media.
Apobec2 expression was measured by qRT-PCR (left), and by western blotting (WB) (right). Apobec2 mRNA expression was normalized by Gapdh expression (n=3,
mean±SD) and as a reference the expression level in primary myoblasts (MB control) was measured (n=2, mean±SD). Myog and actin WB were used as controls
for myogenic differentiation and equal loading, respectively. b DNA methylation and gene expression analyses of Myogenin were performed in a daily time course
after Dox induction in the inducible myogenic model (n=2). Each circle represents a CpG dinucleotide and its distance to the gene TSS is indicated below. The
colour gradient represents the methylation level indicated in the legend. N.D. means non detectable. c Scheme of the experimental approach followed to
knockdown Apobec2 in the inducible Pax7 model (left). Gene expression and protein level to evaluate Apobec2 knockdown efficiency using two independent
clones were compared to control vector (right) (n=3, mean± SD; representative Apobec2 WB with the corresponding actin loading control). d Myogenin
expression was measured in Pax7-induced myogenic precursors infected with Apobec2 shRNAs 4 days upon lentiviral transduction (right) (n=3, mean± SD).
Representative images of Pax7-induced myogenic precursors infected with Apobec2 shRNAs under differentiation conditions stained with Myogenin and MHC
antibodies. Scale bar: 100 μm. e DNA methylation analysis by sodium bisulphite sequencing of the Myogenin promoter in Pax7 ES-derived myogenic precursors
transduced with Apobec2 shRNA1 and shRNA4 in three biological replicates. Each circle represents a CpG dinucleotide and its distance to the gene TSS is
indicated below. The colour gradient represents the level of methylation indicated in the legend. Statistical significance with respect to the control samples is
indicated with * for p-value < 0.05 applying the Kruskal-Wallis test. ESC embryonic stem cell, TSS transcription start site, shRNA short hairpin RNA
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[51] and represents a switch from a stable repression
mediated by DNA methylation to a more facultative re-
pression mediated by the histone code [4].
Mrf4 is considered a determination and differentiation
myogenic gene and is the only MRF expressed in mature
myofibres [52, 53]. Curiously, Mrf4 promoter is the only
one still repressed by DNA methylation in undifferenti-
ated myoblasts, being highly demethylated only in ma-
ture myofibres where it is highly expressed (Fig. 2a). A
recent paper demonstrated that adult satellite cells
emerged from embryonic founder cells in which the
Mrf4 gene was activated [54], but intriguingly, our re-
sults showed that Mrf4 promoter was completely meth-
ylated in all cell types analysed except in mature
myofibres. Very recently we demonstrated that the mul-
tiple enhancers regulating the complex spatial-temporal
expression of the Myf5/Mrf4 locus during embryogenesis
were specifically demethylated in muscle-committed
cells [16]. In that context, we speculate that complete
demethylation of Mrf4 promoter would be only required
in mature myofibres to fully activate and maintain its
high expression levels.
It is well known that Pax7 has a key role in the forma-
tion and maintenance of muscle committed progenitors.
The engineered iPax7-ESC model let us recapitulate the
commitment of myogenic precursors during embryonic
development and revealed the acquisition of a very simi-
lar DNA methylation signature, compared to primary
muscle cells (Fig. 3c). Importantly, these results support
the use of iPax7 ES-derived myogenic progenitors as a
bona fide model to generate in vitro myogenic precur-
sors with therapeutic purposes. The detailed analysis of
this stepwise model showed that the myogenic differenti-
ation process occurred coupled to a gradual loss of DNA
methylation in myogenic regulatory regions in consecu-
tive waves. Initially, Pax3 enhancer became demethy-
lated before Pax7 induction in line with its expression
pattern, which is not restricted to the myogenic lineage
[55]. Next, Myf5, MyoD and Myogenin CpG-poor regula-
tory regions became demethylated in iPax7-myoblast
precursors correlating with transcriptional activation
(Fig. 3b-c). Finally, the terminal differentiation myogenic
genes Ckm and Myh8 became simultaneously demethy-
lated and activated during late differentiation, when
iPax7 myogenic precursors differentiated and fused
forming myotubes. This late demethylation wave only
occurred in ES-derived differentiating myocytes and not
in primary myotubes, already demethylated in the MB
stage. This observation points out an epigenetically ac-
centuated myogenic commitment of adult muscle stem
cells compared to myogenic precursors. Importantly, the
loss of DNA methylation only took place upon Pax7
expression (+Dox) indicating that Pax7 is required forskeletal muscle-specific demethylation. Notably, the dif-
ferentially methylated enhancer located at -111 kb of
Myf5 TSS is a direct target of Pax7 in satellite cells [56],
suggesting a link between Pax7 and DNA methylation.
In the last years, several studies have shown the cross-
talk between muscle transcription factors and chromatin
modifiers. In this regard Pax7 has been shown to recruit
the Wdr5-Ash2L-MLL2 histone methyltransferase com-
plex to target genes, in order to stimulate myogenic
transcription [57]. In the same line, MyoD interacts with
the chromatin remodelling complex SWI/SNF [58, 59],
and recruits the histone acetyltransferase P300 and the
histone methyltransferase Ash2L to activate muscle
genes [60–62]. In that context and taking into account
our results we propose a model (Fig. 5) where DNA
methylation prevents inappropriate expression of muscle
genes in ESCs, being removed during the commitment
to the skeletal muscle lineage. The expression of myo-
genic transcription factors might modulate both the re-
cruitment, direct or indirect, of DNA demethylases to
reduce DNA methylation and chromatin compaction,
and histone modifiers/chromatin remodelers to activate
transcription of muscle genes. In proliferating myoblasts,
the differentiation genes would be kept in a silenced/
poised transcriptional state by PRC2 and HDACs com-
plexes, whereas in myotubes they would be expressed
upon the recruitment of chromatin activating complexes.
To investigate the possible pathway involved in DNA
demethylation during myogenesis we focused on Apo-
bec2 (Apolipoprotein B mRNA editing enzyme catalytic
polypeptide 2), a member of the cytidine deaminase fam-
ily expressed exclusively in cardiac and skeletal muscle
tissues with unknown functions [63, 64]. The generation
of Apobec2-/- mice showed no major defects in mouse
health, fertility or survival up to 1 year of age [65]. How-
ever, detailed analysis of these animals revealed a 15–20 %
reduction in body mass from birth onwards, a clear histo-
logical evidence of a mild myopathy during aging, and a
markedly increased ratio of slow to fast fibres in soleus
Apobec2-/- muscles [66]. Although the cytidine deaminase
activity of Apobec2 is still controversial [64, 67–69],
it has been reported that during zebrafish develop-
ment Apobec2b stimulates DNA demethylation [70],
and AID/Apobec proteins promote demethylation of
5hmCs in mammals [21]. Our results showed that
Apobec2 expression was highly induced upon muscle-
commitment in iPax7-myogenic precursors (Fig. 4a)
and, importantly, the downregulation of Apobec2 dramat-
ically impaired muscle differentiation, abolishing myo-
genin and myosins expression (Fig. 4d), in agreement with
experiments performed on C2C12 myoblast cells showing
that Apobec2 was required for myotube formation [71].
Recently, Powell and co-workers reported that Apobec2
had an essential role during retina and optic nerve
Fig. 5 Model for the epigenetic control of muscle-specific gene expression during myogenesis. Diagram proposing a simplified model where
myogenic transcription factors would activate muscle genes by modulating both the recruitment, direct or indirect, of DNA demethylases to reduce DNA
methylation levels and chromatin compaction, and histone modifiers/chromatin remodelers to activate transcription of muscle genes. In proliferating
myoblasts, the differentiation genes would be kept in a silenced/poised transcriptional state by PRC2 and HDACs complexes, whereas in myotubes they
would be expressed upon the recruitment of chromatin activating complexes. Abbreviations: DDMs DNA demethylases, HATs histone acetyltransferases,
HDACs histone deacetylases, HMTs histone methyltransferases, PRC2 Polycomb repressive complex 2, SWI/SNF SWI/SNF ATP-dependent
chromatin remodelling complex, YY1 Yin and Yang 1
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DNA methylation during tissue-regeneration were inde-
pendent of Apobec2 expression [73]. Interestingly, our re-
sults showed that Myogenin DNA methylation levels were
significantly higher in iPax7-myoblast precursors when
Apobec2 activity was abolished, correlating with gene si-
lencing (Fig. 4e). However, the MyoD and Myf5 DNA
methylation changes observed upon Apobec2 knockdown
were smaller, and not statistically significant. That could
be due to the existence of some cell heterogeneity during
the process of Pax7-dependent myogenic induction, which
could mask the demethylation events occurring in MyoD
and Myf5 genes. Another explanation could be related to
the fact that MyoD and Myf5 play a very early role in
muscle-lineage determination, as mouse embryos with
targeted mutation in both genes lack myoblasts and differ-
entiated skeletal muscles [74]. Therefore, we cannot rule
out the involvement of other mechanisms, such us Tet-
mediated DNA demethylation, in the epigenetic activation
of these two early-induced genes. Altogether, our results
suggest that Apobec2 might participate in the active DNA
demethylation process required to drive myogenic differen-
tiation. Apobec2 has emerged as an important myogenic
regulator that would merit further studies regarding how it
is recruited to genomic loci affecting epigenetic regulation.
Conclusions
This study presents for the first time the DNA methyla-
tion dynamics of the principal genes orchestrating themyogenic determination and differentiation programs
during myogenesis. Our results show that a common
DNA demethylation signature is required to acquire and
maintain the muscle-cell identity, and that downregula-
tion of the muscle-specific cytidine deaminase Apobec2
in ES-derived myogenic precursors reduces myogenic-
associated DNA demethylation and impairs muscle dif-
ferentiation. Importantly, we have also identified muscle
epigenetic markers that may be useful to ensure the effi-
cient and safe generation of ES- and iPS-derived myo-
genic progenitors for therapeutic applications.
Methods
Skeletal muscle stem cells isolation and culture
Skeletal muscle stem cells were isolated from hind limb
muscles of 6- to 8-week-old mice (kindly provided by
P. Muñoz Cánoves of the Pompeu Fabra University,
Barcelona) as described in [75]. After mechanical and
enzymatic dissociation with 1 % Pronase protease (Cal-
biochem), the filtered digest was centrifuged through
an isotonic Percoll (Amersham) gradient (60 % overlaid
with 20 %) and cells were collected from the gradient
interface, resuspended in growth medium (GM: Ham’s
F-10 plus 20 % FBS, 5 ng/ml bFGF, 100 U/ml penicillin
and 100 μg/ml streptomycin) and grown on tissue culture
dishes coated with 0.05 mg/ml collagen I from rat tail
(Becton and Dickinson) to amplify the myoblast popula-
tion. To induce myotube formation, confluent proliferat-
ing primary myoblasts were grown on matrigel coated
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Dickinson) and switched to differentiation medium the
next day (DM: DMEM plus 2 % horse serum, 100 U/ml
penicillin and100 μg/ml streptomycin (Life Technologies))
for 4 days. Myofibres directly isolated from EDL muscles
were kindly provided by S. Gutarra. Two biological repli-
cates of each experiment were performed and analysed.
Mouse protocols were approved by the Animal Care and
Use Committee of the PRBB, and the Ethical Committee
for Animal Experimentation of the Government of
Catalonia.
Cell lines
ESCs were kindly provided by M. Carrió (cGR8) and F.
Lluís (E14Tg2), NPCs were also provided by F. Lluís and
HL1 cells by S. Pagans. MEFs and HEK 293 T cells were
cultured in DMEM complemented with 10 % fetal
bovine serum, 1 % penicillin/streptomycin and 2 mM
Glutamax (Life Technologies).
Inducible Pax7-ESC-derived myogenic model
The inducible cell line encoding full length murine Pax7
(iPax7) was generated as previously described in [41].
iPax7-ESCs were co-cultured with irradiated mouse
embryonic fibroblasts (MEFs), obtained as described in
[76]. The co-culture was maintained in knockout
DMEM (Invitrogen) supplemented with 15 % ES quali-
fied FBS (Invitrogen), 1 % penicillin/streptomycin (Invi-
trogen), 2 mM Glutamax, 0.1 mM b-mercaptoethanol
and 1000 U/ml Lif (Millipore) medium. To induce cellu-
lar differentiation ESCs were trypsinized, resuspended in
EB differentiation medium (EBM) containing Iscove-
modified DMEM (Life Technologies), 15 % ES quali-
fied FBS (Life Technologies), 1 % penicillin/strepto-
mycin, 2 mM Glutamax, 200 mg/ml iron-saturated
transferrin (Sigma-Aldrich), 4.5 mM monothioglycerol
(Sigma-Aldrich, and 50 mg/ml ascorbic acid (Sigma-
Aldrich), and preplated for 30 min on gelatin-coated
dishes to remove MEFs. After counting, 1x106 cells
were plated in 15 cm petri dishes and placed on a
shaker at 60 RPM/min (37 °C, 5 % CO2) to induce EB
formation (this time point is referred to as day 0 of the
EB differentiation protocol). Pax7 expression was induced
after 3 days of differentiation by adding doxycycline (Dox)
(D9891, Sigma-Aldrich) to the culture medium at a final
concentration of 1 μg/ml. At day 5, mesodermal precursors
corresponding to the PDGFRα+/FLK1- cell population were
isolated by FACS (FACS Aria II - BD Biosciences) using
PE-conjugated anti-mouse CD140a (PDGFRα; RRID:
AB_657615) and APC-conjugated anti-mouse CD309
(FLK1; RRID: AB_657865) (E-Bioscience). Sorted cells
from Dox-treated and untreated EBs were cultured on
gelatin-coated flasks in EBM (with or without Dox) for
5 more days before harvesting them (which we refer toas iPax7 myoblasts (MB) precursor cells). To induce
the myotube formation, the iPax7-MB precursors were
cultured on DMEM (Invitrogen) supplemented with
2 % horse serum (Hyclone), 1 % penicillin/streptomycin
and 2 mM glutamax and, importantly, Dox was removed
to allow terminal myogenic differentiation, which physio-
logically only occurs upon Pax7 expression withdrawal.
Lentiviral transduction
Apobec2 shRNAs cloned in pLKO.1-puro lentiviral con-
structs were purchased by the Biomedical Genomic Cen-
ter at the University of Minnesota. After testing different
clones for Apobec2 down-regulation compared to the con-
trol vector, the following clones were selected: shRNA#1
CCTGGCTTCCTGATTCTACTT and shRNA#4 GCTA
CCAGTCAACTTCTTCAA. Lentiviruses were produced
by co-transfecting pLKO.1-puromycine vector and the
packaging constructs (pVSV-G, pREV and pD8.74 [77])
in HEK 293 T cells using Lipofectamine LTX-Plus Re-
agent (Life Technologies) following the manufacturer’s
instruction. Supernatants containing the lentiviral parti-
cles were collected 36 h after transfection, passed
through a 0.45 μm filter and used to transduce iPax7
MB precursors. Cells were harvested for gene expression
and DNA methylation analyses 4 days after transduction.Gene expression analysis
Total RNA was isolated with a miRNeasy Mini Kit (Qia-
gen) according to the manufacturer’s instructions and
retro-transcribed with SuperScript® III Reverse Tran-
scriptase (Life Technologies). cDNA was amplified by
qRT-PCR using LightCycler480 (Roche) with Fast Start
DNA Master Sybr Green I mix (Roche) and expression
results were normalized with Gapdh or 18S expression.
Expression results for the Pax7-induced ES-derived
muscle differentiation model were plotted relative to
iPax7 myogenic precursors (set to 1) for myogenic
markers and to iPax7-ESC for pluripotency markers.
Primer sequences are listed in Additional file 6.
Immunofluorescence staining
Cells cultured on slides were fixed with 4 % paraformal-
dehyde for 10 min, permeabilized with 0.1 % Triton X-
100 (Life Technologies) for 10 min and blocked with
5 % BSA reagent (Vector Labs) for 30 min, before incu-
bating with primary antibodies Myogenin (1:250, clone
F5D, BD Biosciences; RRID: AB_39638) and MHC
(1:20, clone MF20, Developmental Studies Hybridoma
Bank; RRID: AB_2147781). Alexafluor 555-goat anti-
mouse (1:500, Invitrogen; RRID: AB_2535844) was used
as secondary antibody and preparations were mounted
with Prolong mounting media with DAPI (Life Tech-
nologies) to counter stain nuclei.
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pyrosequencing validation
Genomic DNA was isolated after an overnight Protein-
ase K digestion (Invitrogen) followed by an RNaseA
(Invitrogen) treatment for 1 h. After phenol-chloroform
extraction, ethanol precipitation and NanoDrop quantifi-
cation, genomic DNA was run in a 1 % agarose gel
stained with ethidium bromide to check its integrity.
Sodium bisulphite conversion was performed using
300 ng of genomic DNA with an EZ DNA Methylation-
Gold™ Kit (ZymoResearch, Orange) according to the
manufacturer’s instructions. Treated DNA was amplified
as previously described [78], purified and sequenced by
Sanger direct sequencing. In Additional file 7 the specific
primers for the methylation profiling of the different gen-
omic regions are listed. In Additional file 8 it is shown
how the DNA methylation range was quantified and the
corresponding validation by pyrosequencing. Briefly, to
assess the DNA methylation state of each cytosine we ana-
lysed the raw sequencing electropherograms visualized
with Geospiza FinchTV software. We compared the DNA
reference sequence with the obtained sequence after bisul-
phite conversion. In bisulphite-treated DNA followed by
PCR amplification the methylated cytosines remain cyto-
sines (C, blue peak in the sequencing electropherogram),
whereas the unmethylated cytosines become thymines (T,
red peak in the sequencing electropherogram). Notice that
when reverse sequencing primers are used the cytosines
will be read as guanines (G, black peak) and the thymines
as adenines (A, green peak). When a single peak was
observed in the original C position, we considered the
population homogenous, indicating a blue peak (C) that
the cytosine was methylated in all cells and a red peak (T)
that the cytosine was unmethylated in all cells. When two
peaks were shown in the original C position it corre-
sponded to a mixed population. In these cases, the height
of each peak was measured to assess the proportion of
each population. For the sake of simplicity, the methyla-
tion level was ranked in five different intervals 0–0.2,
0.21–0.4, 0.41–0.6, 0.61–0.8 and 0.81–1, which reflected
the DNA methylation state of this particular cytosine. In
Additional file 8b the pyrosequencing validation of the
methylation state of three CpGs located in Myh1 and
Myh8 promoter regions is shown. Notably, the linear
correlation between the results obtained by both method-
ologies was R2 = 0.98 for Myh1 and R2 = 0.91 for Myh8.
Western blot analysis
Proteins were extracted using RIPA buffer supplemented
with protease inhibitors (Complete Mini, Roche) and
quantified using Bradford reagent (Sigma). An amount
of 50 ug of proteins were separated on a 12 % SDS-
PAGE gel and successively transferred on PVDF mem-
brane (Millipore). The membrane was blocked using 5 %BSA in TBST and then incubated overnight with the in-
dicated antibody diluted in blocking solution. Antibodies
used were: anti-Apobec2 (1:1000, sc-98335 Santa Cruz
Biotechnology; RRID: AB_2258415), anti-MyoG (1:1000,
clone F5D Developmental Studies Hybridoma Bank;
RRID: AB_2146602), and anti-Actin (1:2000, MAB1501
Millipore; RRID: AB_2223041). HRP-conjugated anti-
mouse or anti-rabbit IgG (1:20000, Amersham ECL
Western Blotting Reagent Pack RPN2124) were used as
secondary antibodies. Positive and negative controls
used for the identification of Apobec2 consisted of skel-
etal muscle and brain protein extracts, respectively.
Availability of data and materials
All genomic representations containing reference genes,
CpG islands and ChIP-seq data were integrated, ex-
plored and visualized using the Integrative Genomics
Viewer [79]. All ChIP-seq data, with the exception of the
H3K27Ac and p300 data from proliferating and differen-
tiated C2C12 (MB and MT) [38], were generated by the
ENCODE Project Consortium [37]. GEO accession
numbers are listed in Additional file 9. Sodium bisul-
phite sequencing data and Kruskal-Wallis test of sodium
bisulphite data were done with the Methylation Plotter
web tool [80]. Supporting data containing the individual
gene expression values are shown in Additional file 10.
Additional files
Additional file 1: CpG-island promoters of developmental genes are
unmethylated. DNA methylation state of CpG islands overlapping and
surrounding the promoter region of Pax3 (a) and Pax7 (b) genes in
myogenic (MB, MT, MF) and non-myogenic samples (ESC). CpG islands
are indicated in green and regions analysed by sodium bisulphite
sequencing are shown in red. Each circle represents a CpG dinucleotide and
its distance to the gene TSS is indicated below. The colour gradient
represents the percentage of methylation indicated in the legend.
Abbreviations: ESC, embryonic stem cell; MB, myoblast; MT, myotube;
MF, myofiber; TSS, transcription start site. c. DNA methylation state of -5 kb
distal regulatory region for MyoD was analysed by sodium bisulphite
sequencing in ESC and myoblast samples, and represented as above.
(PDF 171 kb)
Additional file 2: CpG-poor promoters of pluripotency genes became
methylated during muscle-lineage specification. a. Scheme of the Sox2
and Fgf4 loci showing in dark green the CpG island and in light green
the unmethylated state of the analysed CpGs by HAIB-Methyl RRBS from
ENCODE Project in human ESCs (H1-ESCs), myoblasts (HSMM), myotubes
(HSMMtube) and myofibers (skeletal_7N). b. DNA methylation state of
Pou5f1 (left) and Dppa4 (right) promoters in myogenic (MB, MT, MF) and
non-myogenic samples (ESC, NPC, HL1, MEF). Analysed regions are
indicated in red and biological duplicates are shown in the circle
charts, where each circle represents a CpG dinucleotide and its distance to
the gene TSS is indicated below. The colour gradient represents the
percentage of methylation indicated in the legend. Bar charts show the
gene expression values measured by qRT-PCR and normalized by Gapdh
and 18S, respectively (n = 2, mean ± SD). N.D. means non detectable. c.
Histone marks distribution and p300 binding in ESC (blue), MB (yellow) and
MT (red) obtained from ENCODE Project and Dynlatch’s lab [38]. Abbreviations:
ESC, embryonic stem cell; HL1, cardiomyocyte; MB, myoblast; MT, myotube;
MF, myofiber; MEF, mouse embryonic fibroblast; NPC, neuronal
precursor cell; TSS, transcription start site. (PDF 153 kb)
Carrió et al. BMC Biology  (2016) 14:30 Page 13 of 15Additional file 3: Pax7-induced ESC-derived myogenic model. Represen-
tative fields showing the morphology of iPax7 ES-derived cells at
different stages of differentiation with or without Pax7 induction
(100x magnification). Arrows show plurinucleated myotubes. ESCs,
MB and MT precursors were cultured in monolayer, whereas EBs
day 3 were grown in suspension. Abbreviations: EBs, embryoid bodies; ESCs,
embryonic stem cells; MB, myoblast; MT, myotube; iPax7, inducible Pax7;
Dox, Doxycycline. (PDF 25026 kb)
Additional file 4: Dnmt and Tet expression profiles during Pax7-induced
ESC derived myogenic model and Apobec2 western blot analysis.
Expression levels of Dnmt1, Dnmt3a and Dnmt3b (a) and Tet1, Tet2 and
Tet3 (b) were measured by qRT-PCR at the successive time points of iPax7
ESC-derived myogenic model, with or without doxycycline, and normalized
by Gapdh expression (n = 3, mean ± SD). c. Apobec2 western blots were
performed on total protein extracts from skeletal muscle tissue (SK M)
and brain (left), and muscle progenitor cells (iPax7-MB) and mature
myotubes (C2C12-MT) (right). Skeletal muscle shows a specific Apobec2
band (32 kDa), whereas multiple bands are detected in brain tissue and
in muscle cells. (PDF 798 kb)
Additional file 5: DNA methylation analysis of MyoD and Myf5 genes in
Apobec2 depleted cells. DNA methylation analysis by sodium bisulphite
sequencing of the -20 kb MyoD enhancer (a) and promoter and -111 kb
enhancer of Myf5 gene (b) in Pax7 ES-derived myogenic precursors
transduced with Apobec2 shRNA1 and shRNA4, in three biological
replicates. Each circle represents a CpG dinucleotide and its distance
to the gene TSS is indicated below. The colour gradient represents
the methylation level indicated in the legend. (PDF 100 kb)
Additional file 6: Primer sequences used by qRT-PCR expression
analysis. (DOCX 12 kb)
Additional file 7: Primer sequences used by assessing the DNA
methylation profiles of different genomic regions either by Sanger
sequencing or pyrosequencing. (DOCX 16 kb)
Additional file 8: Explanation and validation of the Sanger sequencing-
based DNA methylation method. a. Quantification of DNA methylation
state by bisulphite conversion followed by Sanger direct sequencing.
DNA methylation state of each cytosine was analysed comparing the
DNA reference sequence with the raw sequencing electropherograms of
the bisulphite-converted sequence, visualized with Geospiza FinchTV
software. The methylation level was ranked in five different intervals
0–0.2, 0.21–0.4, 0.41–0.6, 0.61–0.8 and 0.81–1, which reflects the DNA
methylation state of this particular cytosine. Detailed explanations
about how the methylation interval was assigned for each cytosine are in
the Methods section. b. Correlation between Sanger and Pyrosequencing
results. In the left panels are shown the DNA methylation state of three
CpGs located in Myh1 and Myh8 promoter regions, in two embryonic
stem cells ESC 1-2 and two primary myogenic precursor cells MPC 1-2.
For each CpG it is shown the raw chromatogram obtained by Sanger
sequencing with our corresponding assigned methylation interval and
the methylation value obtained by pyrosequencing, which is inside the
interval in most of the cases (right top scatter plots). On the right bottom
scatter plots are shown the high linear correlation between Sanger
sequencing and pyrosequencing results, with R2 = 0,98 for Myh1 and
R2 = 0,91 for Myh8. (PDF 2930 kb)
Additional file 9: GEO accession numbers for histone marks ChIP-seq
data generated by the ENCODE Project Consortium and Dynlacht’s
laboratory. (DOCX 43 kb)
Additional file 10: Individual gene expression values normalized by a
reference gene are shown for the two or three biological replicates
analysed. (XLSX 49 kb)Abbreviations
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